17β-HSD10 is a mitochondrial enzyme that catalyzes the steroidal oxidation of a hydroxy group to a keto group and, thus, is involved in maintaining steroid homeostasis. The druggability of 17β-HSD10 is related to potential treatment for neurodegenerative diseases, for example, Alzheimer's disease or cancer. Herein, steroidal derivatives with an acidic hemiester substituent at position C-3 on the skeleton were designed, synthesized, and evaluated by using pure recombinant 17β-HSD10 converting 17β-estradiol to estrone. Compounds 22 (IC50 = 6.95 ± 0.35 μM) and 23 (IC50 = 5.59 ± 0.25 μM) were identified as the most potent inhibitors from the series. Compound 23 inhibited 17β-HSD10 activity regardless of the substrate. It was found not cytotoxic toward the HEK-293 cell line and able to inhibit 17β-HSD10 activity also in the cellular environment. Together, these findings support steroidal compounds as promising candidates for further development as 17β-HSD10 inhibitors.

Faculty of Science Department of Chemistry University of Hradec Kralove Rokitanskeho 62 500 03 Hradec Kralove Czech Republic

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Flemingovo namesti 2 Prague 6 166 10 Czech Republic

ACS Omega. 2024 Mar 26;9(14):16879. doi: 10.1021/acsomega.4c02539. PubMed

Zobrazit více v PubMed

He X.-Y.; Merz G.; Yang Y.-Z.; Mehta P.; Schulz H.; Yang S.-Y. Characterization and localization of human type10 17b-hydroxysteroid dehydrogenase. Eur. J. Biochem. 2001, 268, 4899–4907. 10.1046/j.0014-2956.2001.02421.2421.x. PubMed DOI

Wohlfarter Y.; Eidelpes R.; Yu R. D.; Sailer S.; Koch J.; Karall D.; Scholl-Bürgi S.; Amberger A.; Hillen H. S.; Zschocke J.; et al. ost in promiscuity? An evolutionary and biochemical evaluation of HSD10 function in cardiolipin metabolism. Cell. Mol. Life Sci. 2022, 79 (11), 562. PubMed PMC

He X. Y.; Merz G.; Mehta P.; Schulz H.; Yang S. Y. Human brain short chain L-3-hydroxyacyl coenzyme A dehydrogenase is a single-domain multifunctional enzyme. Characterization of a novel 17beta-hydroxysteroid dehydrogenase. J. Biol. Chem. 1999, 274 (21), 15014–15019. 10.1074/jbc.274.21.15014. PubMed DOI

Carlson E. A.; Marquez R. T.; Du F.; Wang Y.; Xu L.; Yan S. S. Overexpression of 17β-hydroxysteroid dehydrogenase type 10 increases pheochromocytoma cell growth and resistance to cell death. BMC Cancer 2015, 15, 166.10.1186/s12885-015-1173-5. PubMed DOI PMC

Yang S. Y.; He X. Y.; Isaacs C.; Dobkin C.; Miller D.; Philipp M. Roles of 17β-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders. J. Steroid Biochem. Mol. Biol. 2014, 143, 460–472. 10.1016/j.jsbmb.2014.07.001. PubMed DOI

Zhang A.; Zhang J.; Plymate S.; Mostaghel E. A. Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression. Horm Cancer 2016, 7 (2), 104–113. 10.1007/s12672-016-0250-9. PubMed DOI PMC

Snaterse G.; van Dessel L. F.; van Riet J.; Taylor A. E.; van der.; Vlugt-Daane M.; Hamberg P.; de Wit R.; Visser J. A.; Arlt W.; Lolkema M. P.. et al.11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration JCI Insight, 2021, 6 ((11)), . PubMed PMC

Salas S.; Jézéquel P.; Campion L.; Deville J. L.; Chibon F.; Bartoli C.; Gentet J. C.; Charbonnel C.; Gouraud W.; Voutsinos-Porche B.; et al. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2. Int. J. Cancer 2009, 125 (4), 851–860. 10.1002/ijc.24457. PubMed DOI

Porcu P.; Barron A. M.; Frye C. A.; Walf A. A.; Yang S. Y.; He X. Y.; Morrow A. L.; Panzica G. C.; Melcangi R. C. Neurosteroidogenesis Today: Novel Targets for Neuroactive Steroid Synthesis and Action and Their Relevance for Translational Research. J. Neuroendocrinol. 2016, 28 (2), 12351.10.1111/jne.12351. PubMed DOI PMC

Vinklarova L.; Schmidt M.; Benek O.; Kuca K.; Gunn-Moore F.; Musilek K. Friend or enemy? Review of 17β-HSD10 and its role in human health or disease. J. Neurochem 2020, 155 (3), 231–249. 10.1111/jnc.15027. PubMed DOI

Schmidt M.; Benek O.; Vinklarova L.; Hrabinova M.; Zemanova L.; Chribek M.; Kralova V.; Hroch L.; Dolezal R.; Lycka A.; et al. Benzothiazolyl Ureas are Low Micromolar and Uncompetitive Inhibitors of 17β-HSD10 with Implications to Alzheimer’s Disease Treatment. Int. J. Mol. Sci. 2020, 21 (6), 2059.10.3390/ijms21062059. PubMed DOI PMC

Benek O.; Hroch L.; Aitken L.; Dolezal R.; Guest P.; Benkova M.; Soukup O.; Musil K.; Kuca K.; Smith T. K.; et al. 6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17β-HSD10 and potential drugs for Alzheimer’s disease treatment: Design, synthesis and in vitro evaluation. Med. Chem. 2017, 13 (7), 345–358. 10.2174/1573406413666170109142725. PubMed DOI

Aitken L.; Benek O.; McKelvie B. E.; Hughes R. E.; Hroch L.; Schmidt M.; Major L. L.; Vinklarova L.; Kuca K.; Smith T. K.; et al. Novel Benzothiazole-based Ureas as 17β-HSD10 Inhibitors, A Potential Alzheimer’s Disease Treatment. Molecules 2019, 24 (15), 2757.10.3390/molecules24152757. PubMed DOI PMC

Benek O.; Vaskova M.; Miskerikova M.; Schmidt M.; Andrys R.; Rotterova A.; Skarka A.; Hatlapatkova J.; Zdarova Karasova J.; Hroch L.; et al. Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation. Eur. J. Med. Chem. 2023, 258, 11559310.1016/j.ejmech.2023.115593. PubMed DOI

Schmidt M.; Vaskova M.; Rotterova A.; Benek O.; Fiandova P.; Miskerikova M.; Zemanova L.; Musilek K. Physiologically relevant fluorescent assay for identification of 17β-HSD10 inhibitors. J. Neurochem. 2023, 167 (2), 154–167. 10.1111/jnc.15917. PubMed DOI

Kissinger C. R.; Rejto P. A.; Pelletier L. A.; Thomson J. A.; Showalter R. E.; Abreo M. A.; Agree C. S.; Margosiak S.; Meng J. J.; Aust R. M.; et al. Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer’s disease therapeutics. J. Mol. Biol. 2004, 342 (3), 943–952. 10.1016/j.jmb.2004.07.071. PubMed DOI

Morsy A.; Maddeboina K.; Gao J.; Wang H.; Valdez J.; Dow L. F.; Wang X.; Trippier P. C. Functionalized Allopurinols Targeting Amyloid-Binding Alcohol Dehydrogenase Rescue Aβ-Induced Mitochondrial Dysfunction. ACS Chem. Neurosci. 2022, 13 (14), 2176–2190. 10.1021/acschemneuro.2c00246. PubMed DOI

Ayan D.; Maltais R.; Poirier D. Identification of a 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitor: a tool to investigate the role of type 10 in Alzheimer’s disease and prostate cancer. ChemMedChem 2012, 7 (7), 1181–1184. 10.1002/cmdc.201200129. PubMed DOI

Boutin S.; Roy J.; Maltais R.; Alata W.; Calon F.; Poirier D. Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17β-hydroxysteroid dehydrogenase type 10. Bioorg. Med. Chem. Lett. 2018, 28 (22), 3554–3559. 10.1016/j.bmcl.2018.09.031. PubMed DOI

Boutin S.; Maltais R.; Roy J.; Poirier D. Synthesis of 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitors: Selectivity, metabolic stability and enhanced potency. Eur. J. Med. Chem. 2021, 209, 11290910.1016/j.ejmech.2020.112909. PubMed DOI

Dilly S. J.; Clark A. J.; Marsh A.; Mitchell D. A.; Cain R.; Fishwick C. W. G.; Taylor P. C. A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment. Cancer Lett. 2017, 393, 16–21. 10.1016/j.canlet.2017.01.042. PubMed DOI

Metodieva V.; Smith T.; Gunn-Moore F. The Mitochondrial Enzyme 17βHSD10 Modulates Ischemic and Amyloid-β-Induced Stress in Primary Mouse Astrocytes. eNeuro 2022, 9 (5), ENEURO.0040-22.2022.10.1523/ENEURO.0040-22.2022. PubMed DOI PMC

Pinna G.; Almeida F. B.; Davis J. M. Allopregnanolone in Postpartum Depression. Front Glob Womens Health 2022, 3, 82361610.3389/fgwh.2022.823616. PubMed DOI PMC

Cornett E. M.; Rando L.; Labbé A. M.; Perkins W.; Kaye A. M.; Kaye A. D.; Viswanath O.; Urits I. Brexanolone to Treat Postpartum Depression in Adult Women. Psychopharmacol Bull. 2021, 51 (2), 115–130. PubMed PMC

Lamb Y. N. Ganaxolone: First Approval. Drugs 2022, 82 (8), 933–940. 10.1007/s40265-022-01724-0. PubMed DOI

Hamilton N. M.; Dawson M.; Fairweather E. E.; Hamilton N. S.; Hitchin J. R.; James D. I.; Jones S. D.; Jordan A. M.; Lyons A. J.; Small H. F.; et al. Novel steroid inhibitors of glucose 6-phosphate dehydrogenase. J. Med. Chem. 2012, 55 (9), 4431–4445. 10.1021/jm300317k. PubMed DOI

MacNevin C. J.; Atif F.; Sayeed I.; Stein D. G.; Liotta D. C. Development and screening of water-soluble analogues of progesterone and allopregnanolone in models of brain injury. J. Med. Chem. 2009, 52 (19), 6012–6023. 10.1021/jm900712n. PubMed DOI

Tserfas M. O.; Levina I. S.; Kuznetsov Y. V.; Scherbakov A. M.; Mikhaevich E. I.; Zavarzin I. V. Selective synthesis of the two main progesterone metabolites, 3α-hydroxy-5α-pregnanolone (allopregnanolone) and 3α-hydroxypregn-4-en-20-one, and an assessment of their effect on proliferation of hormone-dependent human breast cancer cells. Russian Chem. Bull. 2020, 69, 552–557. 10.1007/s11172-020-2797-4. DOI

Kudova E.; Chodounska H.; Slavikova B.; Budesinsky M.; Nekardova M.; Vyklicky V.; Krausova B.; Svehla P.; Vyklicky L. A New Class of Potent N-Methyl-D-Aspartate Receptor Inhibitors: Sulfated Neuroactive Steroids with Lipophilic D-Ring Modifications. J. Med. Chem. 2015, 58 (15), 5950–5966. 10.1021/acs.jmedchem.5b00570. PubMed DOI

Xu S.; Toyama T.; Nakamura J.; Arimoto H. One-pot reductive cleavage of exo-olefin to methylene with a mild ozonolysis-Clemmensen reduction sequence. Tetrahedron Lett. 2010, 51 (34), 4534–4537. 10.1016/j.tetlet.2010.06.102. DOI

Matousova M.; Soucek R.; Tloustova E.; Slavikova B.; Chodounska H.; Mertlikova-Kaiserova H.; Kudova E. Pregn-5-en-3β-ol and androst-5-en-3β-ol dicarboxylic acid esters as potential therapeutics for NMDA hypofunction: In vitro safety assessment and plasma stability. Steroids 2019, 147, 4–9. 10.1016/j.steroids.2018.09.012. PubMed DOI

Artursson P.; Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 1991, 175 (3), 880–885. 10.1016/0006-291X(91)91647-U. PubMed DOI

Rubas W.; Jezyk N.; Grass G. M. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm. Res. 1993, 10 (1), 113–118. 10.1023/A:1018937416447. PubMed DOI

Krausova B.; Slavikova B.; Nekardova M.; Hubalkova P.; Vyklicky V.; Chodounska H.; Vyklicky L.; Kudova E. Positive Modulators of the N-Methyl-d-aspartate Receptor: Structure-Activity Relationship Study of Steroidal 3-Hemiesters. J. Med. Chem. 2018, 61 (10), 4505–4516. 10.1021/acs.jmedchem.8b00255. PubMed DOI